InMed Pharmaceuticals Plans 1-for-10 Share Consolidation
Bitget2026/11/02 21:28- InMed Pharmaceuticals plans a 1-for-10 share consolidation in connection with its proposed merger with Mentari Therapeutics.
- Completion is expected after market close November 4, 2026, conditional on shareholder approval of three merger-related proposals at that day's meeting.
- Outstanding Common Shares would fall from 5,493,735 to approximately 549,374 before the merger.
- Consolidation-adjusted trading on the Nasdaq Capital Market is expected to begin at market open November 5, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
Crypto prices
More
